M&A Deal Summary |
|
|---|---|
| Date | 2025-05-05 |
| Target | Previse |
| Sector | Life Science |
| Buyer(s) | Castle Biosciences |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2007 |
| Sector | Healthcare Services |
| Employees | 784 |
| Revenue | 332M USD (2024) |
Castle Biosciences is a developer and commercializes diagnostic and prognostic tests for dermatologic cancers. Castle Biosciences was founded in 2007 and is based in Friendswood, Texas.
| DEAL STATS | # |
|---|---|
| Overall | 5 of 5 |
| Sector: Life Science M&A | 4 of 4 |
| Type: Add-on Acquisition M&A Deals | 3 of 3 |
| State: Maryland M&A | 1 of 1 |
| Country: United States M&A | 5 of 5 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-04-04 |
AltheaDx
San Diego, California, United States AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenetics, or PGx. AltheaDx's product testing portfolio enables personalized therapeutic decisions for patients suffering from some of the most prevalent clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders, and pain. AltheaDx was founded in 1998 and is based in San Diego, California. |
Buy | $65M |
